Impact of tricuspid regurgitation on survival in patients with cardiac amyloidosis

Abstract

Aims

Tricuspid regurgitation (TR) is a common finding and has been associated with poorer outcome in patients with heart failure. This study sought to investigate the prognostic value of TR in patients with cardiac amyloidosis (CA).

Methods and results

Two‐hundred and eighty‐three patients with CA—172 (61%) wild‐type transthyretin amyloidosis (ATTRwt) and 111 (39%) light‐chain amyloidosis (AL)—were consecutively enrolled between December 2010 and September 2019. Transthoracic echocardiographies at time of diagnosis were reviewed to establish the presence and severity of TR and its relationship with all‐cause mortality during patients' follow‐up. Seventy‐four (26%) patients had a moderate‐to‐severe TR. Moderate‐to‐severe TR was associated with New York Heart Association status ( P < 0.001), atrial fibrillation ( P = 0.003), greater levels of natriuretic peptides ( P = 0.002), worst renal function ( P = 0.03), lower left ventricular ejection fraction ( P = 0.02), reduced right ventricular systolic function ( P = 0.001), thicker tricuspid leaflets ( P = 0.019), greater tricuspid annulus diameter ( P = 0.001), greater pulmonary artery pressure ( P = 0.001), greater doses of furosemide ( P = 0.001), and anti‐aldosterone ( P = 0.01) and more anticoagulant treatment ( P = 0.001). One hundred and thirty‐four (47%) patients met the primary endpoint of all‐cause mortality. After multivariate Cox analysis, moderate‐to‐severe TR was significantly associated with mortality [hazard ratio 1.89, 95% confidence interval (1.01–3.51), P = 0.044] in patients with ATTRwt. There was no correlation between TR and death [hazard ratio 0.84, 95% confidence interval (0.46–1.51), P = 0.562] in patients with AL.

Conclusions

Moderate‐to‐severe TR is frequent in CA, and it is an independent prognosis factor in patients with ATTRwt but not in patients with AL.